A Feasibility Randomised Controlled Trial of Early Vitrectomy for Post-operative Exogenous Endophthalmitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-12

Study Completion Date

2025-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomised clinical trial will explore the feasibility and acceptability of carrying out early vitrectomy surgical treatment compared to standard treatment in acute endophthalmitis. We will investigate the effectiveness of early vitrectomy plus intravitreal antibiotics compared to standard care intravitreal antibiotic injections in the management of postoperative exogenous endophthalmitis. This is a feasibility trial that will evaluate the expected effect size with which to inform the design of a definitive randomized trial of this question.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Endophthalmitis Vitrectomy Study (EVS)

NCT00000130

Endophthalmitis Eye Infections

COMPLETED PHASE3

Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis

NCT01760746

Proliferative Diabetic Retinopathy (PDR)

COMPLETED

The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery

NCT02767219

Glaucoma

COMPLETED PHASE3

Ocular Discomfort Assessment After Intravitreal Injections

NCT02806830

Macular Degeneration Diabetic Retinopathy Retinal Artery Occlusion +1 more

COMPLETED NA

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

NCT01787669

Diabetes Diabetic Macular Oedema Diabetic Macular Edema +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EVIAN Study is a multicentre, feasibility, randomised controlled trial to evaluate the effect of early vitrectomy surgery on acute endophthalmitis.

Patients with postoperative exogenous endophthalmitis following any ocular surgery/procedure/injection intervention will be recruited at 48 hours following initial presentation.

Patients with vision of 35 ETDRS letters or better are ineligible for the trial, and would continue on standard of care management. Patients with vision of worse than 35 ETDRS letters will be eligible for the study. At the 48-hour time-point, eligible patients will be randomised in a 1:1 ratio.

The treatment group will undergo vitrectomy within 48 hours of randomisation. The control group will have continued intravitreal antibiotic eye injections according to local protocols. If the vision reaches perception of light, then a vitrectomy surgery would be considered as part of standard of care at 12-15 days. Follow up will be for 6 months in both groups.

Visual acuity, funds photography, B-scan ultrasound, and optical coherence tomography (OCT) scanning will be performed from baseline until the final follow-up at 24 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endophthalmitis Postoperative Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised control trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Vitrectomy Group

Vitrectomy surgery plus intravitreal antibiotics

Group Type EXPERIMENTAL

Vitrectomy

Intervention Type PROCEDURE

Vitrectomy within 48 hours of randomisation

Intravitreal antibiotics

Intervention Type PROCEDURE

Intravitreal Antibiotics at 48 hours

Control Group

Intravitreal antibiotics

Group Type ACTIVE_COMPARATOR

Intravitreal antibiotics

Intervention Type PROCEDURE

Intravitreal Antibiotics at 48 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitrectomy

Vitrectomy within 48 hours of randomisation

Intervention Type PROCEDURE

Intravitreal antibiotics

Intravitreal Antibiotics at 48 hours

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient over 18 years of age
* Patient has capacity to give informed consent
* Patient has not previously been enrolled in this study in regards to their other eye
* Diagnosis of postoperative endophthalmitis at any time-point following an ocular surgery/procedure/injection
* Patient is healthy to undergo vitrectomy surgery
* Symptomatic Visual loss attributable to POE
* Best corrected visual acuity worse than 35 ETDRS letters, including CF, HM and POL vision

Exclusion Criteria

* Patient suffered a major thromboembolic event within the past 3 months as (defined as TIA, Stroke, or MI)
* Known adverse reaction to intravitreal antibiotics (amikacin/vancomyin/cephalosporins)
* Blood pressure greater than 200 systolic or 100 diastolic
* Any other condition that in the opinion of the investigator would preclude participation in the study (such as unstable medical status or severe disease that would make it difficult for the patient to be able to complete the study)
* The patient will use an investigational drug during the study
* History of optic atrophy in the study eye
* Corneal oedema/haze that would prevent visualisation of fundus to perform vitrectomy surgery
* Patient over the age of 95 who present with POE should immediately be placed on the pre-screening log as ineligible

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No